As of November 6, 2026, Humacyte, Inc. is a publicly traded company (Nasdaq: HUMA). The largest holder reporting an active stake on Schedule 13D is Fresenius Medical Care AG, at 9.5%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, January 9, 2026).
Is this your company?
About to sign with, pay or invest in Humacyte, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Humacyte, Inc. a real, registered company?
- Humacyte, Inc. files with the SEC under CIK 1818382 (its SEC filings).
- Its shares are listed under the ticker HUMA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Durham, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under HUMACYTE, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Scott Coward (Form 8-K filed 2026-09-28). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fresenius Medical Care Holdings, Inc. (filed 2026-07-13).
Who are Humacyte, Inc.'s owners and officers?
Humacyte, Inc.: incorporated in Delaware; business address in Durham, North Carolina; industry Biological Products, (No Diagnostic Substances) (Form D, 2026-09-28).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-08-18 | Fresenius Medical Care Holdings, Inc. | 4.9% |
| Schedule 13G/A, 2026-07-28 | Blackrock, Inc. | 1.5% |
| Schedule 13D/A, 2026-07-13 | Fresenius Medical Care Holdings, Inc. | 6.8% |
| Schedule 13G, 2026-06-22 | Davidson Kempner Capital Management LP | 4.74% |
| Schedule 13D/A, 2026-06-15 | Fresenius Medical Care Holdings, Inc. | 6.8% |
| Schedule 13D/A, 2026-04-27 | Fresenius Medical Care Holdings, Inc. | 8.4% |
| Schedule 13D/A, 2026-03-24 | Fresenius Medical Care Holdings, Inc. | 8.4% |
| Schedule 13D/A, 2026-01-09 | Fresenius Medical Care Ag | 9.5% |
| Schedule 13D/A, 2025-10-16 | Fresenius Medical Care Ag | 9.9% |
Questions about who owns Humacyte, Inc.
Who owns Humacyte, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Humacyte, Inc.: Fresenius Medical Care Ag (9.5%, Schedule 13D/A, filed 2026-01-09).
When did Fresenius Medical Care Ag buy into Humacyte, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Fresenius Medical Care Ag on this page is the Schedule 13D/A, filed 2025-10-16, reporting 9.9%; its latest, Schedule 13D/A filed 2026-01-09, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 9 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Humacyte, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Humacyte, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Humacyte, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-28 | Scott Coward | appointed |
Which insiders own Humacyte, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Fresenius Medical Care Holdings Inc.: 18,312,735 shares (6.6% of shares outstanding) (Form 4, 2025-12-08).
- , a director: 1,392,091 shares (0.50% of shares outstanding), held indirectly through By Ayabudge LLC (Form 4, 2025-08-20).
- , the chief executive and president: 1,392,091 shares (0.50% of shares outstanding), 243,851 held directly and 1,148,240 indirectly (Form 4, 2025-08-20).
- , the chief financial officer and chief corp. dev. officer: 307,813 shares (0.11% of shares outstanding), 267,213 held directly and 40,600 indirectly (Form 4, 2026-05-20).
- , the chief medical officer: 272,713 shares (0.10% of shares outstanding) (Form 4, 2026-05-20).
Shares outstanding: 277,798,105 as of 2026-08-10, from the company's latest SEC cover page.
How much has Humacyte, Inc. raised?
No fundraising or offering filing from Humacyte, Inc. is on file with us.
Keep reading
More on Humacyte, Inc. and the records around it.
Humacyte, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Aug 2026
Companies that share a holder
- M.H. Davidson & Co. also filed stake reports on 17 other companies: Greenland Mines Ltd (Sep 2026), Qtrex Quantum Ltd. (Aug 2026), AIB Data Centers Inc. (Aug 2026)
- BlackRock, Inc. also filed stake reports on 1596 other companies: AvePoint, Inc. (Nov 2026), BIOMARIN PHARMACEUTICAL INC (Nov 2026), MSG RANGERS CORP (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/humacyte